Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $32.82 (market cap $3.52B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.1× GraniteShares 2x Long NVDA Daily ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NVDL | SYRE | |
|---|---|---|
Market Cap | $3.52B | $7.35B |
Volume | 8,416,483 | 1,624,631 |
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $108.92 |
52-Week Low | $21.76 | $22.18 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.58 with a 1.81% daily gain. Technical indicators show a mixed but leaning bullish signal, with moving averages supporting upward momentum while oscillators remain neutral. The ETF tracks NVIDIA's performance, which recently beat Q2 2027 earnings estimates, maintaining its leadership in AI innovation. Recent news highlights both the potential for continued AI-driven growth and concerns about leveraged ETF performance discrepancies compared to the underlying asset.
The outlook for NVDL is tied to NVIDIA's AI dominance and market momentum, offering leveraged exposure to chip sector growth. Key risks include volatility decay inherent in daily-reset leveraged ETFs and dependency on NVIDIA's ability to sustain its competitive edge. Investor sentiment is cautiously optimistic, balancing strong technical breakouts against warnings about leveraged ETF performance gaps.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
